Conclusion
Vaccines that cover HPV 16, 58, 52, 51, and 18 are likely to provide
excellent protection against VaIN2+. The rate of multiple HPV infection
in VaIN1 is not statistically different from that in VaIN2+. Cervical
cancer screening has similar sensitivity for VaIN2+ as for CIN2+, with
hr-HPV testing showing higher sensitivity than cytology, and cotesting
showing the highest detection rate. However, in populations after
hysterectomy, cytology and hr-HPV testing have similar sensitivity for
detecting VaIN2+. During colposcopy, acetic acid and Lugol’s iodine
should be applied to cover the entire vaginal mucosa and fornix, and
attention should be paid to abnormal images in the vagina.